Ocular Therapeutix reports $16 million quarterly loss

Ocular Therapeutix reported a net loss of $16 million, or $0.58 per share, in the first quarter of 2017 compared with a net loss of $10.8 million, or $0.44 per share, in the first quarter of 2016, according to a company press release.

Total costs and operating expenses for the quarter totaled $16.1 million compared with $11 million in 2016’s first quarter, with research and development costs decreasing from $7.1 million in 2016’s first quarter to $6.7 million in 2017.

The first quarter of the year saw $0.5 million in revenue from sales of ReSure sealant.

Cash, cash equivalents and marketable securities equaled $80.4 million as of March 31.

Ocular Therapeutix reported a net loss of $16 million, or $0.58 per share, in the first quarter of 2017 compared with a net loss of $10.8 million, or $0.44 per share, in the first quarter of 2016, according to a company press release.

Total costs and operating expenses for the quarter totaled $16.1 million compared with $11 million in 2016’s first quarter, with research and development costs decreasing from $7.1 million in 2016’s first quarter to $6.7 million in 2017.

The first quarter of the year saw $0.5 million in revenue from sales of ReSure sealant.

Cash, cash equivalents and marketable securities equaled $80.4 million as of March 31.